← Back to signals
ORKA
INSIDER SELLOruka Therapeutics, Inc.
Research: Finviz ↗·Perplexity ↗
No convergence signal this quarter — shown because tracked funds have filed 13D/G on this stock.
Days to cover (short int.)
11.6d↓-2.2%
as of 2026-09-15
News Summary
PositiveOruka demonstrated strong clinical momentum with positive Week 28 EVERLAST-A data showing deepening ORKA-001 responses supporting infrequent dosing, backed by a solid ~$496M cash position and bullish analyst consensus (Strong Buy, $120+ targets). However, the stock declined on the positive data announcement, and the CEO has engaged in substantial insider selling (105,910 shares over the past year with no purchases), which warrants monitoring ahead of Phase 2b readouts expected in Q4 2026.
Red flags
- •Stock declined despite positive Week 28 clinical data announcement, suggesting potential disconnect between fundamentals and market perception
- •CEO insider selling pattern: 105,910 shares disposed over the past year with zero purchases, which may signal executive confidence concerns despite public bullish commentary
- •R&D expenses increased 80% YoY ($43.3M vs $24.1M) driven by clinical trials and upfront payments; cash burn trajectory needs monitoring given timeline to Phase 2b and regulatory milestones
Insider Activity
| Name | Title | Type | Shares | Price | Value | Filed | Src |
|---|---|---|---|---|---|---|---|
| Klein Lawrence Otto | Chief Executive Officer | SELL | 9K | $84.03 | $0.72M | 2026-10-01 | ↗ |
| Klein Lawrence Otto | Chief Executive Officer | SELL | 200 | $84.78 | $0.02M | 2026-10-01 | ↗ |
| Klein Lawrence Otto | Chief Executive Officer | SELL | 16K | $83.40 | $1.35M | 2026-10-01 | ↗ |
| Quinlan Paul T | General Counsel | SELL | 3K | $92.37 | $0.27M | 2026-09-21 | ↗ |
| Quinlan Paul T | General Counsel | SELL | 4K | $93.32 | $0.36M | 2026-09-21 | ↗ |
| Agarwal Arjun | Senior Vice President, Finance | SELL | 533 | $95.75 | $0.05M | 2026-09-21 | ↗ |
| Quinlan Paul T | General Counsel | SELL | 601 | $94.44 | $0.06M | 2026-09-21 | ↗ |
| Quinlan Paul T | General Counsel | SELL | 3K | $95.31 | $0.25M | 2026-09-21 | ↗ |
| Goncalves Joana | Chief Medical Officer | SELL | 947 | $95.71 | $0.09M | 2026-09-15 | ↗ |
| Goncalves Joana | Chief Medical Officer | SELL | 2K | $91.10 | $0.22M | 2026-09-15 | ↗ |
| Klein Lawrence Otto | Chief Executive Officer | SELL | 2K | $95.71 | $0.23M | 2026-09-15 | ↗ |
| Quinlan Paul T | General Counsel | SELL | 1K | $95.71 | $0.10M | 2026-09-15 | ↗ |
| Sandler Laura Lee | Chief Operating Officer | SELL | 906 | $95.71 | $0.09M | 2026-09-15 | ↗ |
| Agarwal Arjun | Senior Vice President, Finance | SELL | 560 | $95.71 | $0.05M | 2026-09-15 | ↗ |
| Goncalves Joana | Chief Medical Officer | SELL | 3K | $92.03 | $0.29M | 2026-09-15 | ↗ |
| Goncalves Joana | Chief Medical Officer | SELL | 1K | $92.99 | $0.13M | 2026-09-15 | ↗ |
| Goncalves Joana | Chief Medical Officer | SELL | 100 | $94.22 | $0.01M | 2026-09-15 | ↗ |
| Agarwal Arjun | Senior Vice President, Finance | SELL | 3K | $91.11 | $0.27M | 2026-09-11 | ↗ |
| Agarwal Arjun | Senior Vice President, Finance | SELL | 4K | $92.41 | $0.37M | 2026-09-11 | ↗ |
| Agarwal Arjun | Senior Vice President, Finance | SELL | 2K | $93.26 | $0.21M | 2026-09-11 | ↗ |
| Agarwal Arjun | Senior Vice President, Finance | SELL | 200 | $94.02 | $0.02M | 2026-09-11 | ↗ |
| Sandler Laura Lee | Chief Operating Officer | SELL | 1K | $91.05 | $0.09M | 2026-09-01 | ↗ |
| Sandler Laura Lee | Chief Operating Officer | SELL | 4K | $92.01 | $0.37M | 2026-09-01 | ↗ |
| Klein Lawrence Otto | Chief Executive Officer | SELL | 7K | $90.79 | $0.60M | 2026-09-01 | ↗ |
| Klein Lawrence Otto | Chief Executive Officer | SELL | 64K | $91.90 | $5.84M | 2026-09-01 | ↗ |
| Klein Lawrence Otto | Chief Executive Officer | SELL | 5K | $92.44 | $0.44M | 2026-09-01 | ↗ |
| Goncalves Joana | Chief Medical Officer | SELL | 900 | $109.65 | $0.10M | 2026-08-17 | ↗ |
| Goncalves Joana | Chief Medical Officer | SELL | 300 | $110.52 | $0.03M | 2026-08-17 | ↗ |
| Goncalves Joana | Chief Medical Officer | SELL | 3K | $112.01 | $0.37M | 2026-08-17 | ↗ |
| Goncalves Joana | Chief Medical Officer | SELL | 2K | $112.56 | $0.28M | 2026-08-17 | ↗ |
| Quinlan Paul T | General Counsel | SELL | 4K | $106.05 | $0.38M | 2026-08-14 | ↗ |
| Quinlan Paul T | General Counsel | SELL | 10K | $107.14 | $1.12M | 2026-08-14 | ↗ |
| Quinlan Paul T | General Counsel | SELL | 15K | $107.97 | $1.59M | 2026-08-14 | ↗ |
| Quinlan Paul T | General Counsel | SELL | 10K | $109.11 | $1.11M | 2026-08-14 | ↗ |
| Quinlan Paul T | General Counsel | SELL | 9K | $110.00 | $1.01M | 2026-08-14 | ↗ |
| Quinlan Paul T | General Counsel | SELL | 4K | $111.14 | $0.43M | 2026-08-14 | ↗ |
| Agarwal Arjun | Senior Vice President, Finance | SELL | 2K | $104.67 | $0.22M | 2026-08-13 | ↗ |
| Agarwal Arjun | Senior Vice President, Finance | SELL | 2K | $105.57 | $0.23M | 2026-08-13 | ↗ |
| Agarwal Arjun | Senior Vice President, Finance | SELL | 1K | $106.63 | $0.14M | 2026-08-13 | ↗ |
| Agarwal Arjun | Senior Vice President, Finance | SELL | 2K | $107.71 | $0.23M | 2026-08-13 | ↗ |
| Agarwal Arjun | Senior Vice President, Finance | SELL | 2K | $108.46 | $0.26M | 2026-08-13 | ↗ |
| Goncalves Joana | Chief Medical Officer | SELL | 400 | $84.36 | $0.03M | 2026-07-15 | ↗ |
| Goncalves Joana | Chief Medical Officer | SELL | 2K | $85.86 | $0.21M | 2026-07-15 | ↗ |
| Goncalves Joana | Chief Medical Officer | SELL | 4K | $86.68 | $0.33M | 2026-07-15 | ↗ |
| Goncalves Joana | Chief Medical Officer | SELL | 300 | $87.25 | $0.03M | 2026-07-15 | ↗ |
| Agarwal Arjun | Senior Vice President, Finance | SELL | 300 | $83.07 | $0.02M | 2026-07-13 | ↗ |
| Agarwal Arjun | Senior Vice President, Finance | SELL | 4K | $84.26 | $0.32M | 2026-07-13 | ↗ |
| Agarwal Arjun | Senior Vice President, Finance | SELL | 6K | $84.90 | $0.48M | 2026-07-13 | ↗ |
| Agarwal Arjun | Senior Vice President, Finance | SELL | 300 | $85.63 | $0.03M | 2026-07-13 | ↗ |
| Fairmount Funds Management LLC | — | SELL | 3.6M | $84.43 | $300.01M | 2026-07-01 | ↗ |
| Sandler Laura Lee | Chief Operating Officer | SELL | 2K | $93.85 | $0.21M | 2026-07-01 | ↗ |
| Sandler Laura Lee | Chief Operating Officer | SELL | 2K | $94.75 | $0.21M | 2026-07-01 | ↗ |
| Sandler Laura Lee | Chief Operating Officer | SELL | 500 | $95.47 | $0.05M | 2026-07-01 | ↗ |
Fund 13D/13G Filings (2)
Tracked funds' beneficial-ownership filings on this stock — disclosed within days of a position change, fresher than the quarterly 13F. Since Filing compares the stock to SPY from the filing date (shown for filings within the last 90 days).
| Fund | Form | ∆ Shares | % of Class | Since Filing | Filed | Src |
|---|---|---|---|---|---|---|
| Viking Global | SC 13G/A | −1.2M | 2.5% | -24.1% vs SPY -24.0% abs | 2026-08-14 | ↗ |
| Viking Global | SC 13G/A | — | 5.3% | +69.1% vs SPY +74.6% abs | 2026-05-15 | ↗ |